Cover Image

Editorial: The prevalence and outcomes of perianal Crohn's disease across treatment eras

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Daniel Tassone, Imogen Hartley, Nik Sheng Ding
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	Alimentary Pharmacology & Therapeutics
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Editorial: Managing the Moving Target—Dose Adjustments in Inflammatory Bowel Disease
by: Nicholas Clark, et al.
Published: (2025)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease
by: Tamar Schildkraut, et al.
Published: (2024)

Letter: Steroid Tapering—Is Shorter Duration Better?
by: Juntao Lu, et al.
Published: (2026)

Letter: Ulcerative proctitis—A step towards addressing the knowledge gap, and a call for greater detail, in trial data
by: John David Chetwood, et al.
Published: (2024)

Early ileal resection in Crohn's disease is not associated with severe long‐term outcomes: The ERIC study
by: Nathan Grellier, et al.
Published: (2024)

Editorial: Infliximab induction therapy in pediatric Crohn's disease—A cost‐effective strategy?
by: Neil Chanchlani, et al.
Published: (2024)

Editorial: Upadacitinib in Perianal Crohn's Disease
by: Manjeet Kumar Goyal, et al.
Published: (2026)

Editorial: Infliximab induction therapy in paediatric Crohn's disease — A cost‐effective strategy? Authors' reply
by: Stephanie A. Vuijk, et al.
Published: (2024)

Editorial: Foretelling the future—Emerging role of magnetic resonance enterography as a prognostic tool in Crohn's disease
by: Siri A. Urquhart, et al.
Published: (2024)

Letter: Early real‐world evidence from the United Arab Emirates of the persistence, effectiveness and safety of risankizumab for the treatment of Crohn's disease
by: Maryam Alahmad, et al.
Published: (2024)

Performance of bowel preparation quality scales in patients with Crohn's disease
by: Virginia Solitano, et al.
Published: (2024)

Efficacy and safety of risankizumab by baseline corticosteroid use and achievement of corticosteroid‐free clinical and endoscopic outcomes in patients with moderately to severely active Crohn's disease
by: Stefan Schreiber, et al.
Published: (2024)

Editorial: Surgery to reduce opioid use in Crohn's disease: Does a classic solution address a newer problem?
by: Tarun Chhibba
Published: (2024)

Editorial: Treatments for inflammatory bowel disease across the age‐spectrum—Are they the same?
by: Agnes Hiu Yan Ho, et al.
Published: (2024)

Editorial: Upadacitinib—A Promising Induction Agent for Paediatric Crohn's Disease?
by: Vincenzo Stranges, et al.
Published: (2025)

Editorial: Seton Use in Perianal Fistulising Crohn's Disease. Authors' Reply
by: Jeffrey D McCurdy, et al.
Published: (2025)

Systematic review: Defining, diagnosing and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound
by: Cathy Lu, et al.
Published: (2024)

Letter: Gut microbiota—An overlooked therapeutic target in the prevention of post‐operative recurrence of Crohn's disease
by: D. Bogatic, et al.
Published: (2024)

The use of opioids nine months after surgery for Crohn's disease – a nationwide cohort study
by: Bente Mertz Nørgård, et al.
Published: (2024)

Editorial: Examining Perianal Fistulising Crohn's Disease Through the Lens of Wound Repair
by: Tim Eglinton
Published: (2025)

Editorial: Real‐World Evidence of Upadacitinib—An Effective Induction Therapy for Crohn's Disease?
by: C. Ramos‐Belinchon, et al.
Published: (2025)

Letter: Extreme diagnostic delay due to misdiagnosis of gastrointestinal tuberculosis later diagnosed as postoperative Crohn's disease
by: Abhirup Chatterjee, et al.
Published: (2024)

Editorial: Mesenchymal Stem Cell Therapy for Perianal Fistulising Crohn's Disease—Effective or Hype?
by: Jeffrey D McCurdy, et al.
Published: (2024)

Editorial: Endoscopic Activity is an Essential Tool for Patients' Management, Even in Mild Crohn's Disease
by: Marco Mendolaro, et al.
Published: (2025)

Editorial: Beyond Resection—Rethinking Postoperative Management in Colonic Crohn's Disease. Authors' Reply
by: José Luis Rueda García, et al.
Published: (2026)

Editorial: Real‐World Evidence of Upadacitinib—An Effective Induction Therapy for Crohn's Disease? Authors' Reply
by: Nicolas Richard, et al.
Published: (2025)

Editorial: “Striding” Towards Transmural Healing: Redefining Deep Remission as a Treatment Target in Crohn's Disease
by: Rohita Reji, et al.
Published: (2026)

Editorial: Fistula Calprotectin as a Biomarker of Local Inflammation and Treatment Response in Perianal Fistulising Crohn's Disease. Authors' Reply
by: Runqi Wang, et al.
Published: (2026)

Global perspective on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis ‐ prevalence, clinical impact, economic implications and management strategies
by: Pegah Golabi, et al.
Published: (2024)

Editorial: Development and Validation of a Multimodal Machine Learning Model for Diagnosing and Assessing Risk of Crohn's Disease in Patients With Perianal Fistula
by: Alyssa M. Parian, et al.
Published: (2025)

Letter: Crohn's Disease or Comorbidity? Reassessing Opioid Prescribing Patterns
by: Kuan‐Ju Lin, et al.
Published: (2025)

Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis
by: Antoine Meyer, et al.
Published: (2025)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease—Authors' Reply
by: Virginia Solitano, et al.
Published: (2024)

Letter: Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis
by: Zhidong Zhou, et al.
Published: (2025)

The overlap with metabolic dysfunction‐associated steatotic liver disease negatively affects outcomes of primary biliary cholangitis
by: María Hernández‐Pérez, et al.
Published: (2024)

Editorial: Development and Validation of a Multimodal Machine Learning Model for Diagnosing and Assessing Risk of Crohn's Disease in Patients With Perianal Fistulae: Authors' Reply
by: Lichao Qiao, et al.
Published: (2025)

Natural history of clinical outcomes and hepatic decompensation in metabolic dysfunction‐associated steatotic liver disease
by: Nabil Noureddin, et al.
Published: (2024)

Faecal biomarkers for diagnosis and prediction of disease course in treatment‐naïve patients with IBD
by: Maria Ling Lundström, et al.
Published: (2024)

Editorial: Towards optimal thiopurine therapy for inflammatory bowel disease—authors' reply
by: Abhinav Vasudevan, et al.
Published: (2024)

Upadacitinib for Induction of Remission in Paediatric Crohn's Disease: An International Multicentre Retrospective Study
by: Shlomi Cohen, et al.
Published: (2025)